UndisclosedStrategic acquisitionHealthcare & Life SciencesCompleted
Shionogi completes acquisition of rare-disease drugmaker IntraBio
Osaka-based Shionogi completed its acquisition of IntraBio Inc. The deal adds AQNEURSA (levacetylleucine), approved by the U.S. FDA in 2024 and the European Medicines Agency in January 2026, plus additional rare-disease capabilities. Terms were not disclosed in the release.
Why it matters: The deal expands Shionogi's growing global rare-disease portfolio with an FDA- and EMA-approved product.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →